Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non Operating Income (2021 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Other Non Operating Income for 6 consecutive years, with $119000.0 as the latest value for Q1 2026.

  • For Q1 2026, Other Non Operating Income fell 90.5% year-over-year to $119000.0; the TTM value through Mar 2026 reached $822000.0, down 86.54%, while the annual FY2025 figure was $2.0 million, 69.85% down from the prior year.
  • Other Non Operating Income hit $119000.0 in Q1 2026 for Agios Pharmaceuticals, up from $113000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $3.0 million in Q1 2022 and bottomed at $67000.0 in Q3 2025.
  • Average Other Non Operating Income over 5 years is $1.3 million, with a median of $1.4 million recorded in 2022.
  • Year-over-year, Other Non Operating Income soared 37.81% in 2024 and then tumbled 95.94% in 2025.
  • Agios Pharmaceuticals' Other Non Operating Income stood at $1.4 million in 2022, then grew by 26.23% to $1.7 million in 2023, then fell by 5.25% to $1.6 million in 2024, then crashed by 93.04% to $113000.0 in 2025, then increased by 5.31% to $119000.0 in 2026.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $119000.0, $113000.0, and $67000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.